Type I insulin-like growth factor receptor signaling in hematological malignancies

Oncotarget. 2017 Jan 3;8(1):1814-1844. doi: 10.18632/oncotarget.12123.

Abstract

The insulin-like growth factor (IGF) signaling system plays key roles in the establishment and progression of different types of cancer. In agreement with this idea, substantial evidence has shown that the type I IGF receptor (IGF-IR) and its primary ligand IGF-I are important for maintaining the survival of malignant cells of hematopoietic origin. In this review, we discuss current understanding of the role of IGF-IR signaling in cancer with a focus on the hematological neoplasms. We also address the emergence of IGF-IR as a potential therapeutic target for the treatment of different types of cancer including plasma cell myeloma, leukemia, and lymphoma.

Keywords: IGF-IR; leukemia; lymphoma; plasma cell myeloma.

Publication types

  • Review

MeSH terms

  • Apoptosis / physiology
  • Cell Adhesion / physiology
  • Cell Movement / physiology
  • Cell Proliferation / physiology
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Leukemia / drug therapy
  • Leukemia / pathology*
  • Lymphoma / drug therapy
  • Lymphoma / pathology*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Receptor, IGF Type 1
  • Receptors, Somatomedin / antagonists & inhibitors
  • Receptors, Somatomedin / metabolism*
  • Signal Transduction / physiology*

Substances

  • IGF1 protein, human
  • IGF1R protein, human
  • Receptors, Somatomedin
  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1